Thyroid function and cognitive health: rethinking the relationship between “suboptimal” TSH/FT4 levels and cognitive decline
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70960 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Dvir Dori und 5 weiteren Autor:innen. Beteiligte Einrichtung: Baycrest Academy for Research and Education/Rotman Research Institute, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Thyrotropin, Thyroxine, Cognitive Dysfunction, Cognition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Canadian Institutes of Health Research.
Abstract (Originalsprache)
INTRODUCTION Controversial hypotheses suggest that “suboptimal” thyroid function – defined as higher‐normal thyroid‐stimulating hormone (TSH) (2.0 to 4.5 μIU/mL) or low‐normal free thyroxine (FT4) – may increase risk of cognitive decline and dementia in older patients. METHODS We examined this claim using data from the Canadian Comprehensive Assessment of Neurodegeneration and Dementia cohort (ages 50 to 91; cognitive statuses from unimpaired to dementia, rarer subtypes of dementia excluded). Thyroid function was categorized as “optimal” (TSH < 2.0 μIU/mL or FT4 ≥ 16.74 pmol/L) or “suboptimal.” Six hundred eighty‐eight participants had TSH data, and 476 participants had FT4 data. RESULTS Chi‐squared analyses showed no significant association between “suboptimal” thyroid function and cognitive impairment (TSH: χ 2 = 0.178, p = 0.67; FT4: χ 2 = 0.0027, p = 0.96). True hypothyroidism was rare; 98.6% of those with elevated TSH had normal FT4. DISCUSSION These findings do not support claims that higher‐normal TSH or low‐normal FT4 contribute to cognitive impairment. Caution is warranted against advocating unproven thyroid supplementation for cognitive health. Highlights No link was found between “suboptimal” thyroid function and cognitive impairment. Higher‐normal TSH levels do not indicate dementia risk or hypothyroidism. Among participants with elevated TSH, 98.6% had normal FT4 levels. Redefining TSH cutoffs to 2.0 μIU/mL lacks clinical justification. Findings question the functional medicine approach of thyroid supplementation for cognitive health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baycrest Academy for Research and Education/Rotman Research Institute, Toronto, Ontario, Canada.
- Temerty Faculty of Medicine, University of Toronto Medical Sciences Building, Toronto, Ontario, Canada.
- Department of Medicine (Division of Neurology), University of British Columbia, Victoria, British Columbia, Canada.
- Department of Neurology, Vancouver Island Health Authority, Victoria, British Columbia, Canada.
- Kingston Health Sciences Center, Division of Neurology, Department of Medicine, Queen's University, Kingston, Canada.
- Parkwood Institute, Geriatric Medicine, Department of Medicine, Western University, London, Ontario, Canada.
ORCID-Profile: Dvir Dori, Howard Chertkow
Förderung
- the Canadian Institutes of Health Research
Zitieren
APA
Dori, D., Seixas-Lima, B., Roncero, C., Lahiri, D., Borrie, M., & Chertkow, H. (2025). Thyroid function and cognitive health: rethinking the relationship between “suboptimal” TSH/FT4 levels and cognitive decline. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70960
Vancouver
Dori D, Seixas-Lima B, Roncero C, Lahiri D, Borrie M, Chertkow H. Thyroid function and cognitive health: rethinking the relationship between “suboptimal” TSH/FT4 levels and cognitive decline. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70960
BibTeX
@article{Dori2025,
author = {Dori, Dvir and Seixas-Lima, Bruna and Roncero, Carlos and Lahiri, Durjoy and Borrie, Michael and Chertkow, Howard},
title = {Thyroid function and cognitive health: rethinking the relationship between “suboptimal” TSH/FT4 levels and cognitive decline},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70960}
}
EUVIMED